NCI News
New diagnoses of six major cancer types fell in the early part of the pandemic, according to findings from part 2 of the latest Annual Report to the Nation on the Status of Cancer.
NCI’s Clinical Proteomic Tumor Analysis Consortium releases proteogenomic dataset to accelerate cancer discoveries.
NIH study offers insights into how cells reverse their decision to divide
7/05/2023
An NCI study shows that cell division can be interrupted by withdrawing growth-promoting signals early on in the process.
Biden-Harris Administration launches initiative to improve cancer outcomes in low-income areas
6/26/2023
NCI has awarded $50 million to establish five new centers to study interventions for improving cancer outcomes in persistent poverty communities.
NCI’s ComboMATCH initiative will test new drug combinations guided by tumor biology
6/01/2023
ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.
A new study has outlined opportunities for achieving President Biden and First Lady Biden’s Cancer Moonshot goal of reducing the cancer death rate by at least 50% over the next 25 years.
NCI has helped launch the Pragmatica-Lung Study, a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The simplified trial design aims to increase accessibility for participants.
An NCI study shows that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis.
Cancer Grand Challenges announces global research funding opportunity with nine new challenges
3/08/2023
As part of the Cancer Grand Challenges program, NCI and Cancer Research UK have announced nine new research challenges to tackle profound problems in cancer research.
NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma
12/28/2022
A clinical trial led by NCI has resulted in FDA approval of the immunotherapy drug atezolizumab (Tecentriq) to treat advanced alveolar soft part sarcoma.